

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

GENEOSCOPY, INC.,  
Petitioner,

v.

EXACT SCIENCES CORPORATION,  
Patent Owner.

---

Case No.: IPR2024-00459  
U.S. Patent 11,634,781

---

**PETITION FOR *INTER PARTIES* REVIEW  
OF U.S. PATENT 11,634,781**

**TABLE OF CONTENTS**

I. Introduction ..... 1

II. STANDING AND PROCEDURAL STATEMENTS ..... 2

III. MANDATORY NOTICES & PROCEDURAL STATEMENTS ..... 2

    A. Real Party-in-Interest, 37 C.F.R. § 42.8(b)(1) ..... 2

    B. Related Matters, 37 C.F.R. § 42.8(b)(2) ..... 2

    C. Lead and Backup Counsel and Service Information, 37  
        C.F.R. § 42.8(b)(3) and (b)(4)..... 3

IV. STATEMENT OF THE PRECISE RELIEF REQUESTED AND  
THE REASONS THEREFOR, 37 C.F.R. § 42.22(a) ..... 4

V. BACKGROUND ..... 4

    A. Technical Background ..... 4

        1. Sample Collection and Preparation ..... 4

        2. Fecal Occult Blood Tests ..... 7

        3. Fecal Nucleic Acid Tests ..... 7

    B. The '781 Patent ..... 9

VI. IDENTIFICATION OF THE CHALLENGE, 37 C.F.R. §  
42.104(b)..... 11

    A. The Person of Ordinary Skill in the Art..... 12

    B. References in the Grounds ..... 13

        1. Lenhard (EX1004) ..... 13

        2. Vilkin (EX1005) ..... 14

        3. Itzkowitz (EX1006) ..... 16

        4. Kanaoka (EX1007) ..... 17

        5. Derks (EX1008)..... 19

6.	Shuber (EX1009) .....	19
VII.	DETAILED EXPLANATION OF THE GROUNDS.....	20
A.	Ground I: Lenhard in view of Itzkowitz and Vilkin .....	20
1.	Claim 1 .....	26
2.	Claim 2: “The method of claim 1, further comprising delivering the sealable container containing the removed portion of the fecal sample and said buffer and the sealable collection vessel containing the remaining portion of the fecal sample and said stabilizing buffer to a medical diagnostics laboratory” .	32
3.	Claim 3 .....	33
4.	Claim 4: “The method of claim 3, wherein testing the nucleic acid comprises determining expression from a human gene.” .....	36
5.	Claim 5: “The method of claim 4, wherein determining expression from the human gene comprises testing the nucleic acid for the presence of human DNA having an epigenetic modification.” .....	37
6.	Claim 6: “The method of claim 5, wherein testing the nucleic acid for the presence of human DNA having an epigenetic modification comprises measuring an amount of a methylated human DNA.” .....	37
7.	Claim 7: “The method of claim 5, wherein the epigenetic modification comprises aberrant methylation.” .....	38
8.	Claim 8: “The method of claim 7, wherein the aberrant methylation comprises hypermethylation.” .....	38
9.	Claim 9: “The method of claim 7, wherein the human DNA having an epigenetic modification comprises a gene and/or a promoter region of a gene.” .....	39

10.	Claim 11: “The method of claim 5, wherein testing the nucleic acid for presence of human DNA having an epigenetic modification comprises modifying the nucleic acid with bisulfate ions under conditions wherein unmethylated cytosine is converted to uracil.” .....	39
11.	Claim 14: “The method of claim 3, wherein testing for an amount of blood protein in the removed portion comprises testing for a concentration of hemoglobin in the removed portion.” .....	40
12.	Claim 15: “The method of claim 14, wherein the testing for the concentration of hemoglobin comprises immunochemical detection of hemoglobin.” .....	41
13.	Claims 16-20: “The method of claim 14, wherein the removed portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the removed portion is at least [5, 10, 20, 50, or 200] ng/ml.” .....	41
B.	Ground II: Lenhard in view of Itzkowitz and Vilkin, in further view of Kanaoka.....	43
1.	Claim 12: “The method of claim 4, wherein determining expression from the human gene comprises measuring an amount of RNA expressed from the gene.” .....	43
2.	Claim 13: “The method of claim 12, wherein measuring an amount of RNA expressed from the gene comprises reverse transcriptase polymerase chain reaction (RT-PCR) .....	45
C.	Ground III: Lenhard in view of Itzkowitz and Vilkin, in further view of Derks .....	46
D.	Ground IV: Shuber and Vilkin.....	47
1.	Claim 1 .....	51

2. Claim 2: “The method of claim 1, further comprising delivering the sealable container containing the removed portion of the fecal sample and said buffer and the sealable collection vessel containing the remaining portion of the fecal sample and said stabilizing buffer to a medical diagnostics laboratory” .. 55
3. Claim 3..... 55
4. Claim 4: “The method of claim 3, wherein testing the nucleic acid comprises determining expression from a human gene.” ..... 58
5. Claim 5: “The method of claim 4, wherein determining expression from the human gene comprises testing the nucleic acid for the presence of human DNA having an epigenetic modification.” ..... 58
6. Claim 6: “The method of claim 5, wherein testing the nucleic acid for the presence of human DNA having an epigenetic modification comprises measuring an amount of a methylated human DNA.” ..... 59
7. Claim 7: “The method of claim 5, wherein the epigenetic modification comprises aberrant methylation.”..... 59
8. Claim 8: “The method of claim 7, wherein the aberrant methylation comprises hypermethylation.”..... 59
9. Claim 9: “The method of claim 7, wherein the human DNA having an epigenetic modification comprises a gene and/or a promoter region of a gene.” ..... 60
10. Claim 11: “The method of claim 5, wherein testing the nucleic acid for presence of human DNA having an epigenetic modification comprises modifying the nucleic acid with bisulfate ions under conditions wherein unmethylated cytosine is converted to uracil. . 60
11. Claim 14: “The method of claim 3, wherein testing for an amount of blood protein in the removed

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.